CD123
31 programs · 31 companies
Programs
31
Companies
31
Active Trials
32
Targeting CD123
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| REG-7737 | Regeneron | Preclinical | EpilepsySLE | |
| Ivotuximab | Madrigal Pharma | Phase 2 | LGSPancreatic Ca | |
| Zorizumab | Beam | Approved | PAH | |
| Adagralucimab | Caribou Bio | NDA/BLA | RettLN | |
| TXG-6755 | 10x Genomics | Approved | SMACML | |
| TLX-9288 | Telix Pharma | Phase 2 | Meso | |
| BHC-1366 | Bausch Health | Phase 1 | DMD | |
| CAM-IIT-380 | CAMS | NDA/BLA | Gastric Ca | |
| MOR-923 | MorphoSys (Novartis) | Preclinical | CML | |
| Voxavorutinib | Immunomedics (Gilead) | Phase 3 | MCL | |
| Bemarelsin | Iridex | NDA/BLA | RCCEndometrial Ca | |
| APM-4255 | Aptorum Group | NDA/BLA | CeliacMyelofibrosis | |
| Bemarapivir | CSPC Pharma | Approved | NMOSDPAH | |
| OCT-7288 | Octant Bio | Phase 2/3 | ALSProstate Ca | |
| Polanesiran | Arrowhead Pharma | Phase 1 | DMDSCD | |
| IST-1570 | Istari Onc | Phase 1/2 | SCLC | |
| Tixatuximab | Gland Pharma | Phase 3 | EoEHNSCC | |
| BDT-405 | Black Diamond | Phase 1/2 | CML | |
| CAL-4055 | Calliditas | Phase 3 | BCC | |
| Fixasacituzumab | Innate Pharma | NDA/BLA | PsoriasisUC | |
| 654-2851 | Medigen Vac | Preclinical | PSPALL | |
| OBS-1681 | Obseva (XOMA) | Phase 3 | MDS | |
| BAY-3810 | Bayer AG | Phase 2/3 | PVAngelman | |
| DES-7076 | Destiny Pharma | Phase 2 | Urothelial Ca | |
| ASP-8596 | Aspen Global | Phase 2 | Rett | |
| IRC-IIT-265 | IRCCS San Raffaele | Phase 1/2 | Angelman | |
| RIC-4332 | Gedeon Richter | Phase 3 | CholangiocarcinomaBCC | |
| Rimanaritide | LEO Pharma | Phase 3 | SLERSV | |
| Sovarelsin | Virbac | Phase 1/2 | MSGBM | |
| CDX-409 | Codexis | Approved | NB | |
| CST-7277 | Castle Biosciences | Phase 2/3 | AML |